| VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche RN Kaplan, RD Riba, S Zacharoulis, AH Bramley, L Vincent, C Costa, ... Nature 438 (7069), 820-827, 2005 | 3824 | 2005 |
| Early Lung Cancer Action Project: overall design and findings from baseline screening CI Henschke, DI McCauley, DF Yankelevitz, DP Naidich, G McGuinness, ... The Lancet 354 (9173), 99-105, 1999 | 3331 | 1999 |
| Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance KR Fischer, A Durrans, S Lee, J Sheng, F Li, STC Wong, H Choi, ... Nature 527 (7579), 472-476, 2015 | 1932 | 2015 |
| Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial E Felip, N Altorki, C Zhou, T Csőszi, I Vynnychenko, O Goloborodko, ... The Lancet 398 (10308), 1344-1357, 2021 | 1026 | 2021 |
| Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses S Gnjatic, D Atanackovic, E Jäger, M Matsuo, A Selvakumar, NK Altorki, ... Proceedings of the National Academy of Sciences 100 (15), 8862-8867, 2003 | 987 | 2003 |
| Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database S Paul, NK Altorki, S Sheng, PC Lee, DH Harpole, MW Onaitis, BM Stiles, ... The Journal of thoracic and cardiovascular surgery 139 (2), 366-378, 2010 | 912 | 2010 |
| The lung microenvironment: an important regulator of tumour growth and metastasis NK Altorki, GJ Markowitz, D Gao, JL Port, A Saxena, B Stiles, T McGraw, ... Nature Reviews Cancer 19 (1), 9-31, 2019 | 889 | 2019 |
| TOX is a critical regulator of tumour-specific T cell differentiation AC Scott, F Dündar, P Zumbo, SS Chandran, CA Klebanoff, M Shakiba, ... Nature 571 (7764), 270-274, 2019 | 880 | 2019 |
| Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer AJ Dannenberg, NK Altorki, JO Boyle, C Dang, LR Howe, BB Weksler, ... The lancet oncology 2 (9), 544-551, 2001 | 822 | 2001 |
| Early Lung Cancer Action Project: initial findings on repeat screening CI Henschke, DP Naidich, DF Yankelevitz, G McGuinness, DI McCauley, ... Cancer 92 (1), 153-159, 2001 | 708 | 2001 |
| The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection CG Peyre, JA Hagen, SR DeMeester, NK Altorki, E Ancona, SM Griffin, ... Annals of surgery 248 (4), 549-556, 2008 | 674 | 2008 |
| Immunohistochemical analysis of NY‐ESO‐1 antigen expression in normal and malignant human tissues AA Jungbluth, YT Chen, E Stockert, KJ Busam, D Kolb, K Iversen, ... International Journal of Cancer 92 (6), 856-860, 2001 | 666 | 2001 |
| Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus N Altorki, M Kent, C Ferrara, J Port Annals of surgery 236 (2), 177-183, 2002 | 522 | 2002 |
| Inhibition of cyclooxygenase-2 gene expression by p53 K Subbaramaiah, N Altorki, WJ Chung, JR Mestre, A Sampat, ... Journal of Biological Chemistry 274 (16), 10911-10915, 1999 | 515 | 1999 |
| Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non–small-cell lung cancer (RADIANT): A randomized, double-blind, phase III trial K Kelly, NK Altorki, WEE Eberhardt, MER O'Brien, DR Spigel, L Crinò, ... Journal of Clinical Oncology 33 (34), 4007-4014, 2015 | 499 | 2015 |
| Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind … JF Vansteenkiste, BC Cho, T Vanakesa, T De Pas, M Zielinski, MS Kim, ... The lancet oncology 17 (6), 822-835, 2016 | 490 | 2016 |
| MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival EA Mathé, GH Nguyen, ED Bowman, Y Zhao, A Budhu, AJ Schetter, ... Clinical cancer research 15 (19), 6192-6200, 2009 | 480 | 2009 |
| Cancer-testis genes are coordinately expressed and are markers of poor outcome in non–small cell lung cancer AO Gure, R Chua, B Williamson, M Gonen, CA Ferrera, S Gnjatic, G Ritter, ... Clinical Cancer Research 11 (22), 8055-8062, 2005 | 464 | 2005 |
| Lobar or sublobar resection for peripheral stage IA non–small-cell lung cancer N Altorki, X Wang, D Kozono, C Watt, R Landrenau, D Wigle, J Port, ... New England Journal of Medicine 388 (6), 489-498, 2023 | 448 | 2023 |
| TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer Z Yao, S Fenoglio, DC Gao, M Camiolo, B Stiles, T Lindsted, ... Proceedings of the National Academy of Sciences 107 (35), 15535-15540, 2010 | 441 | 2010 |
